CP-615,003

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CP-615,003
CP-615003 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C20H24FN3O3
Molar mass 373.421 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic; however, poor blood–brain barrier penetration make it primarily useful as a research ligand.[1][2]

References[edit]

  1. ^ Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S (November 2005). "Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33 (11): 1688–99. doi:10.1124/dmd.105.004630. PMID 16081672. 
  2. ^ Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA (August 2007). "Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35 (8): 1341–9. doi:10.1124/dmd.106.013953. PMID 17470526.